Helsinki Declaration

The Declaration of Helsinki is a statement of ethical principles for medical research involving human participants, adopted by the World Medical Association (WMA) in 1964 and revised multiple times since, most recently by the 75th WMA General Assembly in Helsinki in October 2024. It is one of the most influential documents in research ethics, establishing fundamental protections for research participants and guiding the ethical conduct of biomedical research worldwide.

The Declaration of Helsinki was developed in response to documented abuses of human subjects in medical research, including the atrocities of Nazi experimentation revealed at the Nuremberg Trials and subsequent ethical failures in peacetime research. It provides a moral framework that places the well being and rights of individual research participants above the interests of science and society. While not legally binding in itself, the Declaration has been incorporated into national laws, regulatory frameworks, and institutional policies around the world. Ethics committees, institutional review boards, and regulatory agencies reference it as a foundational standard. Many journals require authors to state that their research followed it, and the Declaration itself says that reports of research not in accordance with its principles should not be accepted for publication. For researchers, familiarity with the Declaration of Helsinki is a basic requirement of ethical competence.

The Declaration sets forth principles organized around several key themes. The first is that the health, well being, and rights of the individual research participant take precedence over all other interests. Medical research involving human participants must conform to generally accepted scientific principles, be based on adequate knowledge of the scientific literature, and be described in a research protocol submitted for review by an independent ethics committee before the study begins.

Informed consent is a central requirement. Participants must be fully informed about the nature, purpose, risks, and benefits of the research and must give voluntary, documented consent. Special protections apply to individuals, groups and communities in situations of particular vulnerability. The 2024 revision describes vulnerability as arising from factors that may be fixed or contextual and dynamic, and requires the harms of excluding such groups from research to be weighed against the harms of including them. People who cannot give consent themselves (such as children or individuals with severe cognitive impairment) are in situations of particular vulnerability: consent must be sought from a legally authorized representative, the person's assent must be sought when they are able to give it and their dissent should be respected, and they may be included only if the research is likely to benefit them personally or entails only minimal risk and minimal burden.

The Declaration addresses the use of placebos, stating that a new intervention must be tested against the best proven intervention(s), except in two circumstances: when no proven intervention exists, or when compelling and scientifically sound methodological reasons make a placebo, no intervention, or an intervention other than the best proven one necessary, and the participants who receive it will not be subject to additional risks of serious or irreversible harm as a result of not receiving the best proven intervention. Extreme care must be taken to avoid abuse of this option. This provision has been one of the most debated aspects of the Declaration.

Post trial provisions must be arranged before a clinical trial begins, by sponsors and researchers, to be provided by themselves, healthcare systems or governments for all participants who still need an intervention identified as beneficial and reasonably safe in the trial; exceptions must be approved by a research ethics committee, and participants must be told about these provisions as part of informed consent. This principle is particularly significant for trials conducted in low income settings.

The Declaration also requires that negative as well as positive results be made publicly available (addressing publication bias), that conflicts of interest be disclosed, and that appropriate compensation and treatment be ensured for participants who are harmed as a result of research participation. It also requires research to be registered in a publicly accessible database before the first participant is recruited.

The October 2024 revision replaced "human subjects" with "human participants" in its title and text. It states that, although the Declaration is adopted by physicians, its principles should be upheld by all individuals, teams and organizations involved in medical research, whereas the 2013 version was addressed primarily to physicians. It added calls for meaningful engagement with potential and enrolled participants and their communities before, during and after research, attention to how benefits, risks and burdens are distributed given structural inequities, scientific integrity, and upholding its principles during public health emergencies, and it asks research to strive for environmental sustainability. For data and biological material, it requires free and informed consent for the collection, processing, storage and foreseeable secondary use of biological material and identifiable or re identifiable data, research ethics committee approval and monitoring of databases and biobanks (with reference to the WMA Declaration of Taipei), and ethics committee approval before secondary research when consent is impossible or impracticable.

The Declaration of Helsinki covers medical research involving human participants, including research using identifiable human material or data. Researchers should reference it in their ethics applications and protocols. Ethics committees should use it as a benchmark for reviewing proposed research. It should be consulted whenever ethical questions arise in the design, conduct, or reporting of research involving human participants.

A common error is treating the Declaration of Helsinki as merely a historical document rather than a living and regularly updated set of principles that researchers are expected to follow. Another mistake is applying its principles selectively, emphasizing informed consent while neglecting post trial access obligations or the requirement to publish negative results. Researchers sometimes confuse the Declaration of Helsinki with the Nuremberg Code or the Belmont Report; while these documents are related and complementary, each has distinct provisions and emphasis. Assuming that ethics committee approval automatically ensures compliance with the Declaration is incorrect, as ethics review is one component of a broader set of obligations. Finally, some researchers in non medical fields dismiss the Declaration as irrelevant to their work; it is written for medical research, but its core protections (independent ethics review, free and informed consent, and the priority of participants' rights and interests over research goals) are shared by research ethics frameworks in other fields.

A clinical trial of a new tuberculosis treatment is conducted across 15 sites in sub Saharan Africa and Southeast Asia. The protocol references the Declaration of Helsinki and addresses its key requirements: registration in a public trial registry before the first participant is recruited, independent ethics review at each site, informed consent procedures adapted for participants with limited literacy (using pictorial consent forms and oral explanations in local languages), a Data Safety Monitoring Board to protect participant welfare, a plan, agreed before the trial starts, to provide the study treatment after the trial to all participants who still need it if it proves beneficial and reasonably safe, and a commitment to publishing results regardless of the outcome. When the trial reveals that the new treatment is non inferior to the standard regimen with fewer side effects, the sponsors work with local health authorities to make the treatment available to trial participants and the broader community.